利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.016 秒)

    A novel beta-galactoside-alpha2, 3-sialyltransferase, a gene encoding thereof, and a method for producing thereof
    1.
    发明公开
    A novel beta-galactoside-alpha2, 3-sialyltransferase, a gene encoding thereof, and a method for producing thereof 审中-公开
    新β-半乳糖苷alpha2,3唾液酸转移酶编码基因和生产方法相同的

    公开(公告)号：EP2434018A2

    公开(公告)日：2012-03-28

    申请号：EP11194448.4

    申请日：2006-03-31

    申请人： Japan Tobacco Inc.

    发明人： Takakura, Yoshimitsu ,  Tsukamoto, Hiroshi ,  Yamamoto, Takeshi

    IPC分类号： C12N15/54 ,  C12N9/10 ,  C12P19/26

    CPC分类号： C12P19/26 ,  C12N9/1081 ,  C12Y204/99004

    摘要： The present invention provides a novel β -galactoside- α 2,3-sialyltransferase and a nucleic acid encoding the sialyltransferase. The present invention also provides a microorganism producing the sialyltransferase, as well as a method for producing the sialyltransferase using such a microorganism. The present invention further provides a vector carrying a nucleic acid encoding the sialyltransferase, and a host cell transformed with the vector, as well as a method for producing a recombinant β- galactoside- α 2, 3-sialyltransferase. The present invention further provides a method for preparing a sialylsugar chain, which uses the sialyltransferase of the present invention.

    摘要翻译： 本发明提供了一种新颖的²-galactoside-±2,3-唾液酸转移酶和核酸编码唾液酸转移酶。 本发明因此提供了微生物生产唾液酸转移酶，以及一种使用寻求微生物唾液酸转移酶的方法。 本发明还提供携带核酸编码唾液酸转移酶的载体，并用该载体转化的宿主细胞，以及用于生产重组²-galactoside-±2,3唾液酸转移酶的方法。 本发明进一步提供了用于制备sialylsugar链，其使用本发明的唾液酸转移酶的方法。

    NOVEL ENZYME PROTEIN, PROCESS FOR PRODUCTION OF THE ENZYME PROTEIN, AND GENE ENCODING THE ENZYME PROTEIN
    3.
    发明公开
    NOVEL ENZYME PROTEIN, PROCESS FOR PRODUCTION OF THE ENZYME PROTEIN, AND GENE ENCODING THE ENZYME PROTEIN 审中-公开
    新型酶蛋白，用于生产酶蛋白和酶编码该蛋白质的基因

    公开(公告)号：EP2599867A1

    公开(公告)日：2013-06-05

    申请号：EP11812569.9

    申请日：2011-07-28

    申请人： JAPAN TOBACCO INC.

    发明人： MINE, Toshiki ,  YAMAMOTO, Takeshi ,  KATAYAMA, Sakurako

    IPC分类号： C12N15/09 ,  C12N9/10

    CPC分类号： C12N9/1081 ,  C12Y204/99004

    摘要： The present invention relates to a protein having a β-galactoside-α2,3-sialyltransferase activity but substantially not having any neuraminidase activity, a nucleic acid encoding the enzyme protein, and a method of producing the enzyme using a microorganism transformed with a gene encoding the protein. The protein of the present invention is a modified-type enzyme protein produced by mutating a specific amino acid residue in a β-galactoside-α2,3-sialyltransferase protein derived from a microorganism belonging to the genus Photobacterium of the family Vibrionaceae and thereby substantially inactivating the neuraminidase activity of the protein.

    摘要翻译： 本发明涉及到具有²-galactoside-±2,3-唾液酸转移酶活性，但基本上不具有任何神经氨酸酶活性的核酸编码酶蛋白，并转化生产使用与基因的微生物的酶的方法的蛋白 编码该蛋白。 本发明的蛋白质是通过突变一个²-galactoside-一个特定氨基酸残基从±属于家庭的发光杆菌属弧菌并且因此基本的微生物衍生的2,3-唾液酸转移酶蛋白生产的改性型酶蛋白质 失活蛋白的神经氨酸酶活性。

    O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
    6.
    发明公开
    O-glycan sialylated recombinant glycoproteins and cell lines for producing the same 审中-公开
    乙酰胆碱酯酶重组蛋白质和Zelllinien zur Herstellung davon

    公开(公告)号：EP3042952A1

    公开(公告)日：2016-07-13

    申请号：EP15000016.4

    申请日：2015-01-07

    申请人： CEVEC Pharmaceuticals GmbH

    发明人： Wissing, Silke ,  Wölfel, Jens ,  Faust, Nicole

    IPC分类号： C12N9/10

    CPC分类号： C12N9/1081 ,  C07K14/4753 ,  C07K14/8121 ,  C12P21/005 ,  C12Y204/99001 ,  C12Y204/99004

    摘要： The present invention relates to recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as cell lines that are genetically modified to overexpress a β-galactoside α-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of said recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.

    摘要翻译： 本发明涉及具有高度或完全唾液酸化O-连接的GalNAc聚糖（GalNAc O-聚糖），优选核心GalNAc O-聚糖的重组糖蛋白，以及经遗传修饰以过表达β-半乳糖苷±2的细胞系 ，3-唾液酸转移酶1（ST3Gal1），优选人类ST3Gal1，其可用于产生所述重组糖蛋白。 此外，本发明涉及表达重组糖蛋白的各种方法，增加重组糖蛋白唾液酸化程度的方法以及降低GalNAc O-聚糖的微异质性的方法。 最后，本发明涉及上述细胞系用于生产重组糖蛋白的各种用途，用于增加重组糖蛋白的唾液酸化程度以及降低重组糖蛋白的O-连接的GalNAc聚糖的微异质性。

    O-GLYCAN SIALYLATED RECOMBINANT GLYCOPROTEINS AND CELL LINES FOR PRODUCING THE SAME
    8.
    发明公开
    O-GLYCAN SIALYLATED RECOMBINANT GLYCOPROTEINS AND CELL LINES FOR PRODUCING THE SAME 审中-公开
    用于生产相同的O-甘露糖基化的重组糖蛋白和细胞系

    公开(公告)号：EP3242935A1

    公开(公告)日：2017-11-15

    申请号：EP15821020.3

    申请日：2015-12-15

    申请人： CEVEC Pharmaceuticals GmbH

    发明人： WISSING, Silke ,  WÖLFEL, Jens ,  FAUST, Nicole

    IPC分类号： C12N9/10

    CPC分类号： C12N9/1081 ,  C07K14/4753 ,  C07K14/8121 ,  C12P21/005 ,  C12Y204/99001 ,  C12Y204/99004

    摘要： The present invention relates to recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as cell lines that are genetically modified to overexpress a ²-galactoside ±-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of said recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.